Investment Rating - The investment rating for JD Health (6618.HK) is "Buy" (maintained) [1][9] Core Views - JD Health reported strong revenue and profit growth for 2025, with revenue reaching 73.4 billion RMB, a year-on-year increase of 26.3%. Adjusted operating profit was 4.39 billion RMB, up 69% year-on-year, and adjusted net profit was 6.53 billion RMB, a 36% increase [4][5] - The company is actively building a new infrastructure for "AI + supply chain" in healthcare, enhancing its competitive edge in the pharmaceutical supply chain and the synergy between self-operated and platform services [5][8] Financial Performance - In 2025, revenue from pharmaceutical and health products grew by 25% to 60.9 billion RMB, while revenue from online platforms/digital marketing and other services increased by 34% to 12.6 billion RMB [5] - The annual active user count reached 218 million by December 31, 2025, with a net increase of over 34 million users compared to 2024 [5] - As of December 31, 2025, the company's total cash reserves amounted to 69.5 billion RMB [5] Business Development - JD Health launched over 100 new drugs in 2025, significantly increasing from over 30 in 2024, aiming to become the "first stop for new drug launches" [5] - The company has over 7,000 health supplement brands that have seen continuous sales growth for three consecutive years, focusing on high-potential categories such as infant development and anti-aging [5] - The instant retail business is rapidly developing, with over 300 self-operated pharmacy stores opened, and the JD Home Health Check service saw an 81.9% increase in order volume in 2025 [5][8] Future Projections - Revenue projections for 2026-2028 are 87.4 billion RMB, 100.4 billion RMB, and 112.2 billion RMB, respectively, with adjusted net profits of 6.64 billion RMB, 7.48 billion RMB, and 8.21 billion RMB [7][8] - The company is expected to benefit from the increasing online penetration of pharmaceuticals and the expansion of online medical insurance payment services [8]

Group 1 - Elon Musk has filed a lawsuit against OpenAI and Microsoft, seeking damages between $79 billion and $134 billion, claiming that he contributed significantly to OpenAI's revenue during his involvement [1] - Musk asserts that OpenAI generated approximately $65.5 billion to $109.4 billion in revenue, while Microsoft earned about $13.3 billion to $25.1 billion from this collaboration [1] - The court proceedings for this case are expected to commence in April of this year [1] Group 2 - Lisa Jackson, Apple's head of environmental affairs, is set to retire after 13 years with the company, having played a key role in Apple's sustainability initiatives [2][4] - Jackson led Apple's Racial Equity and Justice Initiative, focusing on improving fairness in education, economic opportunities, and criminal justice [2] - OpenAI's Andrea Vallone, responsible for mental health safety research, has left the company to join Anthropic, highlighting ongoing challenges in addressing user mental health issues in AI interactions [3]